title: Pharmacology of the phosphate binder, lanthanum carbonate.
abstract: Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [(32)P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses.
authors.affiliation: Shire Pharmaceuticals, Hampshire International Business Park, Chineham, Basingstoke, UK. sdamment@shire.com
authors.forename: Stephen J P
authors.initials: SJ
authors.lastname: Damment
mesh_terms: D000536:Aluminum Hydroxide / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D002118:Calcium / Q000378:metabolism; D002119:Calcium Carbonate / Q000494:pharmacology / Q000627:therapeutic use; D002614:Chelating Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D005243:Feces / Q000737:chemistry; D054559:Hyperphosphatemia / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000378:metabolism; D007811:Lanthanum / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D051379:Mice; D010710:Phosphates / Q000032:analysis / Q000493:pharmacokinetics* / Q000652:urine; D010761:Phosphorus Radioisotopes / Q000032:analysis / Q000652:urine; D011073:Polyamines / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017207:Rats, Sprague-Dawley; D000069603:Sevelamer
chemical_list: D002614:Chelating Agents; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D011073:Polyamines; C119467:lanthanum carbonate; D000536:Aluminum Hydroxide; D007811:Lanthanum; D000069603:Sevelamer; D002119:Calcium Carbonate; D002118:Calcium